Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a new strategic partnership with ActiGraph, a leading provider of wearable technologies for clinical trials. The partnership will deliver a broad suite of assessments to provide a fully rounded view of mental and physical capabilities. With both companies holding leading positions in their respective markets, it is anticipated that the co-promotion planned under the agreement will support growth in market share in the future.
ActiGraph’s AccelerantTM partnership program is designed to advance the use of digital health technologies (DHTs) in clinical development by simplifying CROs’ and technology vendors’ access to raw data streams. As part of this strategic partnership, Cambridge Cognition and ActiGraph will combine their collective expertise in digital data collection to enhance assessment capabilities in CNS trials in areas where there is a large unmet need, such as schizophrenia and dementia.
